Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856904 · ClinicalTrials.gov registry record · Phase 4
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
NCT04856904 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 121 participants.
The verdict
NCT04856904, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
Interventions
- DRUG Trifarotene Cream
- DRUG Trifarotene Vehicle Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04856904
The ClinicalTrials.gov registry entry for NCT04856904 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trifarotene Cream is the first listed.
NCT04856904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04856904 about?
NCT04856904 is a clinical study titled "Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation". The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
What is the current status of trial NCT04856904?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2021-05-28. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04856904?
The interventions under investigation include: Trifarotene Cream (DRUG), Trifarotene Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT04856904?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.